Schizophrenia: Reversal of atypical antipsychotic drug-induced obesity and its related metabolic disorders
Schizophrenia: Reversal of atypical antipsychotic drug-induced obesity and its related metabolic disorders
精神分裂症：逆转非典型抗精神病药物引起的肥胖及其相关代谢紊乱
批准号：
nhmrc : 1027493
负责人：
Dr Francesca Fernandez-Enright
金额：
$41.33万
依托单位：
依托单位国家：
澳大利亚
项目类别：
Project Grants
财政年份：
2012
资助国家：
澳大利亚
项目状态：
已结题
起止时间：
2012-01-01 至 2016-12-31
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Atypical antipsychotic drugs such as olanzapine are commonly used to treat mental illnesses such as schizophrenia. While these drugs are effective, their side effects of obesity and metabolic disorders are a major hurdle leading to a serious lack of compliance in taking medication. This project aims to develop better antipsychotic treatment with reduced side-effects including obesity and metabolic disorders for mental illness patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
